E-News - March 2026
Media Spotlight on Alliance Research
Highlighting Alliance Progress and Impact in Research
At the Alliance for Clinical Trials in Oncology (Alliance), we share stories highlighting the progress and impact of cancer research. By shining a light on new clinical trials, scientific discoveries, and the achievements of our investigators, we showcase the progress being made against cancer and the people driving it forward.
These stories raise awareness of the essential role clinical trials play in improving care, alert providers to practice-changing science, help patients find studies that may offer new treatment opportunities, and build trust in the science behind our work. By amplifying these efforts through the media, we strengthen collaboration, accelerate innovation, and move closer to our mission of delivering better treatments and outcomes for people living with cancer.
Below are links to some of our recent media coverage.
Upcoming Alliance Webinar Showcases Cutting-Edge Advances in Cancer Treatment
The Alliance is set to host a public webinar on March 16, 2026, at 1 pm CT, spotlighting critical advances in cancer research presented by Alliance investigators at the recent American Society of Hematology meeting and the San Antonio Breast Cancer Symposium, reported Bioengineer and Science Magazine. The coverage is based on an Alliance news release.
Drug Therapy Reduces Hot Flashes During Prostate Cancer Treatment
An trial led by led by Bradley Stish, MD, of the Mayo Clinic, has found that oxybutynin, a drug used to treat overactive bladder symptoms, reduces hot flashes in men receiving hormone therapy for prostate cancer, reports U.S. News and World Reports. The story is based news release on the results of Alliance A222001 published in the Journal of Clinical Oncology. Other news outlets covering the story include Men’s Journal, Miami Herald, KIMT 3, Sacramento Bee, MSN News, The Sun News, The Cancer Letter, Drugs.com, The Wichita Eagle, Merced Sun-Star, The Macon Telegraph, The State, HealthDay, Newsbreak, Urology Times, ScienMag, Ground News, Medical Xpress, Today Headline, Oncology Central, NewsMax Health, News Medical, Life Technology, Technology Networks, StemCell 101, Time News, First Word Pharma, Newswise, U.S. Pharmacist, Mayo News Network, Medicine Net, Cancer Therapy Advisor, Cancer Today Magazine, Mirage News, Mega Doctor News, Health and Wellbeing – Salud y Bienestar, Unividas, and Hendricks Regional Health.
Targeted Therapy Extends Survival for Advanced Breast Cancer
An international study led by the Alliance Foundation Trials, LLC has found that the targeted therapy palbociclib, a CDK4/6 inhibitor, added to maintenance therapy extends survival by more than 15 months compared with standard therapy alone, reported HealthDay, OncLive, Drugs.com, OncoDaily, HealthMedicine.net, Archynewsy, Australia’s Oncology News, France’s Le Derniere Heure, Germany’s Aerzteblatt, Mexico’s El Tiempo and Medscape, and Spain’s, La Razon, Noticias de Salud, el Periodico Mediterraneo, Europa Press, Gente Digital, Infosalus, Im Medico, NotiUlti and I Sanidad. The news report was based on an Alliance news release on AFT-38 published in the New England Journal of Medicine.
Blood Test After Surgery May Predict Colon Cancer Recurrence Risk
New findings from Alliance (NCCTG) N0147 show testing circulating tumor DNA in patients with stage III colon cancer may help clinicians decide if additional treatments are necessary, reported the Associated Press based a publication in the Journal of Clinical Oncology led by Frank Sinicrope, MD. The story was also covered by CURE, OncoDaily, Yahoo! Finance, StockWatch, France’s Le Lezard, Mexico’s MX Investing, Thailand’s Investing.com.
Positive Results with Abemaciclib for Meningiomas
A national clinical trial led by the Alliance for Clinical Trials in Oncology has found that abemaciclib, an oral cancer drug, may slow tumor growth in patients with aggressive meningiomas that have specific genetic mutations, said Center Network and Spain’s Im Medico. The news on the primary analysis of Alliance A071401 published in Nature Medicine was based on an Alliance news story.
Reducing Risk of Neuroendocrine Tumors
Additional analysis of the Alliance A021602/CABINET trial show cabozantinib improves progression-free survival in patients with previously treated advanced neuroendocrine tumors of the lung and thymus, reported Brazil’s Tudorondonia, Women’s Journal, and Jornal Passaporte. The story reported on data from Alliance A021602/CABINET by Jennifer Chan, MD, presented at ESMO 2025 in Berlin.
ESMO Recommends Physical Exercise for Colon Cancer Based on CALGB Data
Data from clinical trials, including from CALGB (Alliance ) 89803, have led the European Society of Medical Oncology to recommend physical exercise for patients with localized colon cancer, reports Europe Says and Gaceta Medica.
E-News - February 2026
Spotlight on Alliance Trials
